Wang Huanqiu, Sun Ruyu, Yang Sisi, Ma Xueqing, Yu Chengbo
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Institute of Social Medicine, School of Medicine, Zhejiang University, Hangzhou, China.
Front Med (Lausanne). 2022 Aug 3;9:934989. doi: 10.3389/fmed.2022.934989. eCollection 2022.
Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disorder across the world, and non-invasive evaluation approaches are in need to assess NAFLD disease progression. Serum ferritin has been proposed as one of the biomarkers for NAFLD diagnosis in previous studies. This systematic review aims to identify, report, and synthesize studies that investigated the association of serum ferritin level with the various stages of NAFLD among the adult population.
Three databases - MEDLINE, EMBASE, and Scopus - were systematically searched to obtain potentially relevant publications before July 2022. No restrictions were applied to geographical region, study design, publication type and language. The association between serum ferritin level or different ferritin categories and the various stages of NAFLD was the primary outcome of interest. Title and abstract screenings, data extraction and coding, and quality assessment were independently completed by two authors with discrepancies resolved through discussion with a third author.
Thirty-two studies were included and heterogeneity was considerable. The associations between serum ferritin level and the stages of hepatic steatosis, fibrosis, inflammation and ballooning and the occurrence of non-alcoholic steatohepatitis (NASH) were investigated but inconsistent associations were reported. Most studies identified serum ferritin to be a predictor of advanced NAFLD, while several revealed the opposite end.
Serum ferritin could be considered to act as a non-invasive biomarker for assessing various stages of NAFLD. Nevertheless, further studies are still in need to confirm its predictive value since this study reported inconsistent associations based on the qualitative synthesis.
http://www.crd.york.ac.uk/PROSPERO, identifier: CRD42021275630.
非酒精性脂肪性肝病(NAFLD)已成为全球最常见的肝脏疾病,需要采用非侵入性评估方法来评估NAFLD的疾病进展。在先前的研究中,血清铁蛋白已被提议作为NAFLD诊断的生物标志物之一。本系统评价旨在识别、报告和综合研究,这些研究调查了成年人群中血清铁蛋白水平与NAFLD各阶段之间的关联。
系统检索了三个数据库——MEDLINE、EMBASE和Scopus,以获取2022年7月之前可能相关的出版物。对地理区域、研究设计、出版物类型和语言均无限制。血清铁蛋白水平或不同铁蛋白类别与NAFLD各阶段之间的关联是主要关注的结果。标题和摘要筛选、数据提取与编码以及质量评估由两位作者独立完成,如有分歧则通过与第三位作者讨论解决。
纳入了32项研究,异质性较大。研究了血清铁蛋白水平与肝脂肪变性、纤维化、炎症和气球样变阶段以及非酒精性脂肪性肝炎(NASH)发生之间的关联,但报告的关联并不一致。大多数研究确定血清铁蛋白是晚期NAFLD的预测指标,而有几项研究则得出了相反的结论。
血清铁蛋白可被视为评估NAFLD各阶段的非侵入性生物标志物。然而,由于本研究基于定性综合报告了不一致的关联,仍需要进一步研究来证实其预测价值。